Is it safe to use methylprednisolone (corticosteroid) in patients with mitochondrial deficiency?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Using methylprednisolone in patients with mitochondrial deficiency requires caution and should be done only when the benefits outweigh the risks. Corticosteroids like methylprednisolone can potentially worsen mitochondrial function by increasing oxidative stress and impairing energy production in cells already compromised by mitochondrial disease, as suggested by a study on drugs interfering with mitochondrial disorders 1. If treatment is necessary, it should be used at the lowest effective dose for the shortest duration possible, with close monitoring for adverse effects such as metabolic decompensation, lactic acidosis, and worsening of neurological symptoms.

Patients with mitochondrial disease may be more sensitive to the side effects of corticosteroids, including glucose dysregulation, muscle weakness, and electrolyte disturbances. Before initiating treatment, a thorough assessment of the patient's baseline mitochondrial function and consultation with a specialist in mitochondrial medicine is advisable. Alternative anti-inflammatory or immunosuppressive treatments should be considered when appropriate. During treatment, supplementation with antioxidants and mitochondrial cofactors (such as CoQ10, riboflavin, or L-carnitine) may help mitigate some adverse effects, though evidence for this approach is limited 2.

Some studies have investigated the effects of various medications on mitochondrial function, highlighting the importance of cautious use of drugs that may interfere with mitochondrial function in patients with mitochondrial deficiency 3, 4, 5. However, the most recent and highest quality study on this topic is from 2010, which emphasizes the need to avoid or closely monitor the use of mitochondrion-toxic drugs, including corticosteroids, in patients with mitochondrial disorders 1.

Key considerations for the use of methylprednisolone in patients with mitochondrial deficiency include:

  • Close monitoring for adverse effects
  • Use of the lowest effective dose for the shortest duration possible
  • Assessment of baseline mitochondrial function and consultation with a specialist
  • Consideration of alternative treatments
  • Potential supplementation with antioxidants and mitochondrial cofactors.

Overall, the decision to use methylprednisolone in patients with mitochondrial deficiency should be made with caution, taking into account the potential risks and benefits, and with careful monitoring and management to minimize adverse effects.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.